GeneDx Holdings Corp. (WGS)
87.40
+2.22
(+2.60%)
USD |
NASDAQ |
Aug 25, 16:00
87.46
+0.06
(+0.06%)
After-Hours: 19:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.605B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -28.28% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 5.621 |
| Price to Book Value | 10.67 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.6855 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.85% |
Profile
| GeneDx Holdings Corp. is a rare disease diagnosis company, with a mission to empower everyone to live their healthiest life through genomics. The firm combines clinical expertise, advanced technology, and the power of GeneDx Infinity. This foundation powers GeneDx's ExomeDx and GenomeDx tests, enabling clinicians to deliver precise, fast, and actionable diagnoses. The Infinity also fuels discovery for biopharma with AI-driven genomic intelligence. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT. |
| URL | http://www.genedx.com |
| Investor Relations URL | https://ir.genedx.com/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Oct. 27, 2026 (est.) |
| Last Earnings Release | Aug. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| GeneDx Holdings Corp. is a rare disease diagnosis company, with a mission to empower everyone to live their healthiest life through genomics. The firm combines clinical expertise, advanced technology, and the power of GeneDx Infinity. This foundation powers GeneDx's ExomeDx and GenomeDx tests, enabling clinicians to deliver precise, fast, and actionable diagnoses. The Infinity also fuels discovery for biopharma with AI-driven genomic intelligence. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT. |
| URL | http://www.genedx.com |
| Investor Relations URL | https://ir.genedx.com/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Oct. 27, 2026 (est.) |
| Last Earnings Release | Aug. 03, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |